Marianne T. Sweetser

12.3k total citations · 4 hit papers
76 papers, 6.2k citations indexed

About

Marianne T. Sweetser is a scholar working on Molecular Biology, Rheumatology and Immunology. According to data from OpenAlex, Marianne T. Sweetser has authored 76 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 16 papers in Rheumatology and 16 papers in Immunology. Recurrent topics in Marianne T. Sweetser's work include Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), Multiple Sclerosis Research Studies (12 papers) and Porphyrin Metabolism and Disorders (10 papers). Marianne T. Sweetser is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), Multiple Sclerosis Research Studies (12 papers) and Porphyrin Metabolism and Disorders (10 papers). Marianne T. Sweetser collaborates with scholars based in United States, Germany and United Kingdom. Marianne T. Sweetser's co-authors include Minhua Yang, Katherine Dawson, Krzysztof Selmaj, Ludwig Kappos, Ralf Gold, Douglas L. Arnold, Amit Bar‐Or, Eva Havrdová, Sarah Sheikh and Gavin Giovannoni and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Marianne T. Sweetser

72 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 1.3k citations Ralf Gold, Ludwig Kappos et al. profile →
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

2012 1.0k citations Robert J. Fox, J. Theodore Phillips et al. profile →
A Critical Role for Dnmt1 and DNA Methylation in T Cell Development, Function, and Survival

2001 1.0k citations Marianne T. Sweetser et al. profile →
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

2023 149 citations Gabriel J. Robbie, Sean H. Rhyee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marianne T. Sweetser United States	31	2.2k	2.2k	2.1k	1.2k	939	76	6.2k
Vissia Viglietta United States	23	2.0k 0.9×	2.2k 1.0×	662 0.3×	882 0.8×	572 0.6×	65	4.5k
Ronald Herbst United States	39	647 0.3×	2.8k 1.3×	2.4k 1.1×	2.0k 1.7×	445 0.5×	130	6.5k
Horea Rus United States	43	650 0.3×	2.8k 1.3×	1.5k 0.7×	433 0.4×	441 0.5×	126	5.1k
Kamran Ghoreschi Germany	44	980 0.4×	4.4k 2.0×	1.7k 0.8×	2.0k 1.7×	1.3k 1.4×	143	8.2k
Qianjin Lu China	46	653 0.3×	3.1k 1.4×	2.6k 1.3×	702 0.6×	1.4k 1.5×	160	6.9k
Yusuke Nakamura Japan	54	1.3k 0.6×	1.5k 0.7×	4.6k 2.2×	2.1k 1.8×	685 0.7×	160	10.4k
Martha Quezado United States	38	398 0.2×	1.9k 0.9×	1.8k 0.9×	2.1k 1.8×	304 0.3×	153	6.8k
Qianjin Lu China	51	535 0.2×	3.7k 1.7×	3.1k 1.5×	873 0.7×	2.0k 2.1×	172	8.1k
Bo Tang China	31	421 0.2×	1.9k 0.9×	2.5k 1.2×	2.4k 2.0×	386 0.4×	114	6.5k
Westley H. Reeves United States	57	815 0.4×	5.1k 2.3×	3.4k 1.6×	1.2k 1.0×	3.5k 3.7×	209	10.3k

Countries citing papers authored by Marianne T. Sweetser

Since Specialization

Citations

This map shows the geographic impact of Marianne T. Sweetser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marianne T. Sweetser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marianne T. Sweetser more than expected).

Fields of papers citing papers by Marianne T. Sweetser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marianne T. Sweetser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marianne T. Sweetser. The network helps show where Marianne T. Sweetser may publish in the future.

Co-authorship network of co-authors of Marianne T. Sweetser

This figure shows the co-authorship network connecting the top 25 collaborators of Marianne T. Sweetser. A scholar is included among the top collaborators of Marianne T. Sweetser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marianne T. Sweetser. Marianne T. Sweetser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Kon‐Ping, Chih‐Chao Yang, Yi‐Chung Lee, et al.. (2024). Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study. Journal of the Formosan Medical Association. 123(9). 975–984. 2 indexed citations

Sardh, Eliane, Manisha Balwani, David C. Rees, et al.. (2024). Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study. Orphanet Journal of Rare Diseases. 19(1). 365–365. 1 indexed citations

Labeyrie, Céline, et al.. (2024). Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy. European Journal of Neurology. 31(9). e16384–e16384. 2 indexed citations

Fontana, Marianna, John L. Berk, Mazen Hanna, et al.. (2023). Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study. Archives of cardiovascular diseases. 117(1). S34–S35. 1 indexed citations

Hung, Rebecca R., Edileide de Barros Correia, John L. Berk, et al.. (2023). Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension Period. Circulation. 148(Suppl_1). 5 indexed citations

Lee, Ming‐Jen, et al.. (2023). A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort. Journal of the Formosan Medical Association. 123(6). 679–686. 1 indexed citations

Kuter, David J., Herbert L. Bonkovsky, Gayle Ross, et al.. (2023). Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. Journal of Hepatology. 79(5). 1150–1158. 27 indexed citations

Cassiman, David, Raili Kauppinen, Ming‐Jen Lee, et al.. (2022). EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms. Journal of Inherited Metabolic Disease. 45(6). 1163–1174. 14 indexed citations

Hayes, Wesley, David J. Sas, Daniella Magen, et al.. (2022). Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatric Nephrology. 38(4). 1075–1086. 30 indexed citations

10.

Ventura, Paolo, Eliane Sardh, Nicola Longo, et al.. (2022). Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Expert Review of Gastroenterology & Hepatology. 16(9). 879–894. 17 indexed citations

11.

Habtemariam, Bahru, Verena Karsten, Husain Attarwala, et al.. (2020). Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clinical Pharmacology & Therapeutics. 109(2). 372–382. 130 indexed citations

12.

Yamashita, Taro, Mitsuharu Ueda, Haruki Koike, et al.. (2020). Patisiran, an RNAi therapeutic for patients with hereditary transthyretin‐mediated amyloidosis: Sub‐analysis in Japanese patients from the APOLLO study. Neurology and Clinical Neuroscience. 8(5). 251–260. 4 indexed citations

13.

González‐Duarte, Alejandra, T. Coelho, David Adams, et al.. (2019). P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 46(s1). S20–S20. 2 indexed citations

14.

Adams, David, Alejandra González‐Duarte, William O’Riordan, et al.. (2018). Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003). Neurology. 90(15_supplement). 1 indexed citations

15.

Rose, John, Heinz Wiendl, Douglas L. Arnold, et al.. (2015). Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252). Neurology. 84(14_supplement). 2 indexed citations

16.

Amaravadi, Lakshmi, Alvydas Mikulskis, Nisha Lucas, et al.. (2015). Evaluation of Immunogenicity in Patients with Multiple Sclerosis Treated with Daclizumab HYP (P1.147). Neurology. 84(14_supplement). 1 indexed citations

17.

Pozzilli, Carlo, J. Theodore Phillips, Robert J. Fox, et al.. (2015). Long-term Follow-up of the Safety of Delayed-Release Dimethyl Fumarate in RRMS: Interim Results from the ENDORSE Extension Study. (P7.235). Neurology. 84(14_supplement). 5 indexed citations

18.

Kappos, Ludwig, Krzysztof Selmaj, Douglas L. Arnold, et al.. (2015). Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003). Neurology. 84(14_supplement). 3 indexed citations

19.

Fox, Robert J., Krzysztof Selmaj, Kartik Raghupathi, et al.. (2013). Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing–Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study (P01.162). Neurology. 80(7_supplement). 1 indexed citations

20.

Genovese, Mark C., FC Breedveld, P. Emery, et al.. (2009). Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 68(12). 1894–1897. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact